Key Highlights
● Third-quarter Revenue was $982.7 million, down 2.2%, while organic revenue grew 4.7%.
● Adjusted diluted EPS rose 27.2% to $3.09.
● The adjusted Operating Margin widened by 330 basis points to 23.0%.
● 2026 adjusted EPS guidance was raised to $11.35 to $11.55.
Charles River Laboratories International, Inc. (NYSE:CRL), a provider of drug discovery, nonclinical development and Manufacturing support services, lifted its 2026 Earnings guidance with third-quarter results reported in early November. The revised outlook gives investors a defined benchmark for the year's final quarter at a time when the company is reshaping its portfolio. As an S&P 500 constituent in the life sciences tools and services space, Charles River's results are often read as a signal of biopharmaceutical research spending. Investors may view the guidance as a test of whether margin gains can offset a smaller revenue base.
Latest Company Context
For the quarter ended Sept. 26, revenue was $982.7 million, down 2.2% from $1.005 billion as divested businesses fell away, while organic revenue grew 4.7%, the second consecutive quarter of organic growth. GAAP Net Income rose to $333.1 million, or $6.86 per diluted share, but that figure included a $245.6 million, or $5.06 per share, benefit from reversing acquired tax reserves. Non-GAAP net income increased 24.8% to $150.1 million, and adjusted diluted EPS rose 27.2% to $3.09. The adjusted operating margin widened by 330 basis points to 23.0%. Management raised 2026 guidance for organic revenue growth to at least 1.5%, from 0% to 1.0% previously, and for adjusted EPS to $11.35 to $11.55, from $11.15 to $11.45. Reported revenue is expected to decline 1.5% to 2.0% because of divestitures.
Key Business and index Drivers
Segment trends explain much of the guidance change. Discovery and Safety Assessment, the largest unit, generated $596.3 million in revenue with 5.9% organic growth, helped by higher regulated safety assessment study volumes; its adjusted operating margin improved to 26.8% from 25.4%. Manufacturing Solutions grew 7.4% organically to $178.9 million, and its margin jumped to 38.6% from 26.7%, largely because of the CDMO divestiture.
Research Models and Services was the soft spot, with organic revenue down 0.6% and margin slipping to 24.4% as declines in North American small models and large research models offset growth in China. Chief Executive Birgit Girshick said the company was encouraged by the continued strength of the biopharmaceutical Demand environment. DSA net bookings and proposals rose strongly year over year, which may support activity into 2027 if conversion holds. Management has also highlighted projects such as automated Endosafe cartridge manufacturing and the Apollo Orchestrate lab workflow capability as part of its efficiency push.
What Investors Should Watch
The raised range sets a benchmark that investors may compare against delivered results when the company reports full-year figures early in 2027, on a date not yet announced. An initial 2027 outlook, if provided with those results, could indicate whether organic growth is expected to accelerate beyond this year's pace of at least 1.5%. The Research Models and Services segment may draw attention given its negative organic growth, along with any update on large research model sourcing. Investors may also watch how the company deploys Capital following its divestitures and how initiatives under its strategy, including laboratory digitalization, manufacturing automation and alternative testing methods, affect its cost structure. Biotech funding conditions and pharmaceutical research budgets remain external variables that could influence demand for safety assessment work. Margin sustainability in Manufacturing Solutions after the CDMO exit is another point of interest.
Wider Margins on a Smaller Revenue Base
Charles River's third quarter combined modest organic growth with substantially wider margins, a mix that allowed management to lift its earnings outlook even as reported revenue shrinks from divestitures. The one-time tax benefit means GAAP figures overstate underlying profitability, making adjusted measures and segment trends more informative. Whether the company meets its raised range, and how it frames 2027, may shape how investors judge the durability of the recovery in preclinical demand. The RMS segment's direction may be an additional swing factor.






Please wait processing your request...